The best-performing stock from 2005 was a prime example of how biotech stocks are not as capricious as they may seem.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Related links
Rights and permissions
About this article
Cite this article
Ransom, J. Deconstructing Myogen's market cap. Nat Biotechnol 24, 227–228 (2006). https://doi.org/10.1038/nbt0306-227
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt0306-227